D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. - Wikidata - awgldk - TriplyDB

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

http://www.wikidata.org/entity/Q34004789

about

Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review Current trends in drug treatment of obsessive–compulsive disorder Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders NMDA receptors and fear extinction: implications for cognitive behavioral therapy The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder Epigenetic mechanisms underlying extinction of memory and drug-seeking behavior Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment Drug treatment of obsessive-compulsive disorder Aggression in young children with concurrent callous-unemotional traits: can the neurosciences inform progress and innovation in treatment approaches?Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic Animal models of obsessive-compulsive disorder: utility and limitations Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders From the neurobiology of extinction to improved clinical treatments.Obsessive-compulsive disorder in children and adolescents Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.Extinction circuits for fear and addiction overlap in prefrontal cortex D-cycloserine effects on extinction of conditioned responses to drug-related cues Glutamate receptor ion channels: structure, regulation, and function Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors Chronic antidepressant treatment impairs the acquisition of fear extinction.How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD.Neurobiological correlates of cognitions in fear and anxiety: a cognitive-neurobiological information-processing model.Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder Pharmacological enhancement of fear reduction: preclinical models.Stress modulation of cognitive and affective processes From Basic Processes to Real-World Problems: How Research on Emotion and Emotion Regulation Can Inform Understanding of Psychopathology, and Vice Versa Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear Glutamate receptors in extinction and extinction-based therapies for psychiatric illness Extinction of drug- and withdrawal-paired cues in animal models: relevance to the treatment of addiction.D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms.Enhancing exposure-based therapy from a translational research perspective.A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder Generalization of fear inhibition by disrupting hippocampal protein synthesis-dependent reconsolidation process.Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans.A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.

P2860

Q22305514-8AA16A2A-D3DB-4AC6-A72F-9CCF2EFB26E5 Q22305853-9CA390E9-7DE6-4BC0-B4AB-C2FC3E733945 Q24187995-96ECE0B2-9DBC-48F5-8650-238CFE8BFF03 Q24604822-71C4EB7C-9C6A-4F40-8E0B-7596BA623027 Q24605193-B5E2D803-DDC8-43E1-B11C-0A6540584354 Q24615107-F5455B24-85E7-49C9-A895-A07CAD3BAAF9 Q24633004-F04B5A72-ADB4-4940-BD8C-895BA1B04BB2 Q24635508-CBD1344B-536F-49A7-AB0C-6CA10ECC413F Q24642833-3543D104-0BDD-4A7C-B509-BA3EFD6AB085 Q24647348-2D81EEB9-1500-4651-88B0-D249B2AC4C66 Q26783191-365BC6A9-0901-4DCA-ACBF-0C5ECF35E2C0 Q27006437-331C6B37-275B-41EA-9D9C-6220E4BD488E Q27009995-3908BD98-4077-434F-8231-4DA89CCB8CEB Q27011901-546B06C7-8CBB-4622-BA0A-89C1EA8C5199 Q27020941-36E64B96-6F12-4F4D-BBE5-F469B727E432 Q27026313-B972F3DD-C6A4-4B03-B8A8-E7D44A6CF0BC Q28082048-2243E6E5-9C6B-45C8-B691-2DC048113A75 Q28241943-59D7B94C-15DB-4573-A03B-D61C9078B186 Q28266461-3DE21512-B2F6-41BE-9855-F2038462D0B3 Q28290774-D1CEDE28-B9AB-47A3-9AC6-D82937D1353C Q30358603-D5C52AC6-5B41-415F-B40D-43ABF547FF0B Q30375098-BC62DA9E-B720-4162-9ACA-2107F7920E4A Q30426498-77A369F1-4236-441B-B427-4792F8251D96 Q30433318-01887166-3C62-4D73-98A3-68A2A9E4DDA8 Q30437449-877585C3-1E78-4024-B5D0-12414AB98D09 Q30456148-F84EC7B0-BC7E-4D3A-94BA-12A067C7E5B3 Q30458551-19E38516-7A76-4E32-8836-C5BB12479F9F Q30459672-C49A0A40-3F28-4DA3-9072-4788A290752A Q30462825-73EAE008-5415-41DA-A797-C53F040DFB92 Q30464319-20B8BF90-3158-40AE-B5AD-891E5B8DD689 Q30471721-71FF597B-DD79-4393-B55B-F02FBCE645BB Q30475516-A6E3EC3C-7178-46F7-9A55-98AC8BCAAB4E Q30477927-1E176DE7-F34C-421D-8951-A74398109920 Q30478600-55866A41-B42A-49A3-AD7B-55104EA54B0E Q30479274-22732270-7ABB-4622-9050-85B5131A5339 Q30493574-880AAE89-6261-4AFB-8A40-4E477AE40BD5 Q30498105-6EFDC533-ED5C-47B1-9B41-B49A8307A202 Q30503573-5BA62FB2-F197-4CBD-962C-817441E62B62 Q30525198-69BE9D0A-C383-4F91-9B8F-3975E5625A4E Q30585383-3389B117-2BEE-4CE9-A0F2-3CA995D0CE64

P2860

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

http://www.wikidata.org/entity/Q34004789

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@ast

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@en

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@nl

type

label

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@ast

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@en

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@nl

prefLabel

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@ast

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@en

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@nl

P1433

Q34004789-85EDE842-2BF0-478E-8477-89728EFEFE9A

P1476

Q34004789-7BB6780F-4AA4-4005-BEEB-F67F6E3BFD3A

P2093

Q34004789-0C3CF5C8-83CA-469E-88C5-BBE29E7A0196

Q34004789-3AD2BC1B-0B54-49E7-8686-E3EE5CD455BE

Q34004789-4244FFB0-B5C1-4EF2-BF2A-CB4C19A9700F

Q34004789-5EECA0AA-B4B6-4EE9-9C5F-B7368484E6FD

Q34004789-7F32C337-039E-4CD5-BC9A-C8289DE72D79

Q34004789-A7CC9603-7A8A-407E-925D-989B61E01231

Q34004789-B2BDF05A-4B1D-40B2-A76B-839308EFB917

Q34004789-CFF6D428-C4DC-4005-A3A8-ED11E419AC34

Q34004789-E122E643-CD3A-4D6D-9413-8D20D589D8B5

P304

Q34004789-F91F0973-0D1F-4F36-ABAE-B5EB025326CA

P31

Q34004789-53F72CFF-65C0-4488-BB91-21F29782C17B

P356

Q34004789-9C342A93-056A-4F57-9750-1AE1449C2820

P407

Q34004789-674A0B75-4626-4254-A186-1AAC0B458E0E

P433

Q34004789-03578330-613E-490B-8962-84D8D59358F4

P478

Q34004789-E07FA6FB-EE2E-4878-A1A2-658FF9B95D08

P577

Q34004789-79372C7F-625D-4215-8426-BC4463E5DAB6

P5875

Q34004789-B7E35B3E-D3D4-4ED2-8ACC-1CD4CF8E6430

P698

Q34004789-D8E4FA6D-FC34-4AFF-84B2-1BB3F0A13E7D

P356

J.BIOPSYCH.2006.12.020

P1433

Biological Psychiatry

P1476

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.

@en

P2093

Christopher Donahue

http://www.w3.org/2001/XMLSchema#string

David Adson

http://www.w3.org/2001/XMLSchema#string

Edna B Foa

http://www.w3.org/2001/XMLSchema#string

James McCabe

http://www.w3.org/2001/XMLSchema#string

Jillian Peterson

http://www.w3.org/2001/XMLSchema#string

Matt G Kushner

http://www.w3.org/2001/XMLSchema#string

Michael Kotlyar

http://www.w3.org/2001/XMLSchema#string

Paul Thuras

http://www.w3.org/2001/XMLSchema#string

Suck Won Kim

http://www.w3.org/2001/XMLSchema#string

P304

835-838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2006.12.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6248024

http://www.w3.org/2001/XMLSchema#string

P698

17588545

http://www.w3.org/2001/XMLSchema#string